SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

March 02, 2010 10:49 ET

Leading US Based Pharmaceutical Selects OmniComm's TrialMaster for a Phase III International Study

FORT LAUDERDALE, FL--(Marketwire - March 2, 2010) -  OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions, announced today that it was selected by a leading pharmaceutical company to provide OmniComm's flagship EDC Solution, TrialMaster™, for a Phase III study of a drug to test a central nervous system disorder. The contract is for in excess of $200,000 and total revenue generated from this customer exceeds $750,000 over the last six months. 

"OmniComm continues to enhance clinical trial outcomes through TrialMaster," said Stephen Johnson, COO of OmniComm Systems. "We are gratified that another customer has entrusted us with managing their data in a pivotal study. Our ability to attract and retain leading pharmaceutical companies has contributed to a strong start in 2010."

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large-scale institutions to efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information